Unraveling the Role of Huntingtin in Breast Cancer Metastasis

Journal of the National Cancer Institute

Volumn 107, Issue 10, 2015, Pages

  Thion, Morgane S ^a,b,c   McGuire, John R ^a,b   Sousa, Cristovao M ^a,b   Fuhrmann, Laetitia ^a   Fitamant, Julien ^d   Leboucher, Sophie ^a,b   Vacher, Sophie ^a   Du Montcel, Sophie Tezenas ^e,f,g   Bièche, Ivan ^a,h   Bernet, Agnès ^d   Mehlen, Patrick ^d   Vincent Salomon, Anne ^a,g   Humbert, Sandrine ^a,b,i,j,k  

^a INSTITUT CURIE   (France)

^b INSERM U1005   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d UNIVERSITÉ DE LYON   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ UNIV GRENOBLE ALPES   (France)

^j GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^k Chemin Fortuné Ferrini   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; ESTROGEN RECEPTOR; GAMMA UROGASTRONE; HUNTINGTIN; PROGESTERONE RECEPTOR; PROTEIN ZO1; HTT PROTEIN, HUMAN; NERVE PROTEIN; TJP1 PROTEIN, HUMAN; TJP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER GROWTH; CARCINOMA IN SITU; CELL CONTACT; CELL JUNCTION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; TIGHT JUNCTION; TUMOR GROWTH; TUMOR VOLUME; WILD TYPE; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL MOTION; DISEASE COURSE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; CELL MOVEMENT; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; NERVE TISSUE PROTEINS; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84944685439     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv208     Document Type: Article

References (39)

1. Runkle EA, Mu D. Tight junction proteins: from barrier to tumorigenesis. Cancer Lett. 2013;337(1):41-48.
2. Martin TA, Jiang WG. Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta. 2009;1788(4):872-891.
3. Itoh M, Bissell MJ. The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia. 2003;8(4):449-462.
4. Knights AJ, Funnell AP, Crossley M, Pearson RC. Holding Tight: Cell Junctions and Cancer Spread. Trends Cancer Res. 2012;8:61-69.
5. Tokes AM, Szasz AM, Juhasz E, et al. Expression of tight junction molecules in breast carcinomas analysed by array PCR and immunohistochemistry. Pathol Oncol Res. 2012;18(3):593-606.
6. Hoover KB, Liao SY, Bryant PJ. Loss of the tight junction MAGUK ZO-1 in breast cancer: relationship to glandular differentiation and loss of heterozygosity. Am J Pathol. 1998;153(6):1767-1773.
7. Martin TA, Watkins G, Mansel RE, Jiang WG. Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer. 2004;40(18):2717-2725.
8. Gauthier LR, Charrin BC, Borrell-Pages M, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118(1):127-138.
9. Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001;293(5529):493-498.
10. Colin E, Zala D, Liot G, et al. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J. 2008;27(15):2124-2134.
11. Humbert S, Bryson EA, Cordelieres FP, et al. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell. 2002;2(6):831-837.
12. Pineda JR, Pardo R, Zala D, Yu H, Humbert S, Saudou F. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease. Mol Brain. 2009;2(1):33.
13. Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet. 2008;17(24):3837-3846.
14. Moreira Sousa C, Humbert S. Huntingtin: Here, There, Everywhere! Journal of Huntington's disease. 2013;2(2):395-403.
15. Elias S, Thion MS, Yu H, et al. Huntingtin regulates mammary stem cell division and differentiation. Stem Cell Reports. 2014;2(4):491-506.
16. Elias S, McGuire JR, Yu H, Humbert S. Huntingtin is required for epithelial polarity through RAB11A-mediated apical trafficking of PAR3-aPKC. PLoS Biol. 2015;13(5):e1002142.
17. Moreira Sousa C, McGuire JR, Thion MS, et al. The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling. EMBO Mol Med. 2013;5(2):309-325.
18. Awadelkarim KD, Callens C, Rosse C, et al. Quantification of PKC family genes in sporadic breast cancer by qRT-PCR: evidence that PKCiota/lambda overexpression is an independent prognostic factor. Int J Cancer. 2012;131(12):2852-2862.
19. Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene. 2001;20(56):8109-8115.
20. Prat A, Cheang MC, Martin M, et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol. 2013;31(2):203-209.
21. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145.
22. Fitamant J, Guenebeaud C, Coissieux MM, et al. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer. Proc Natl Acad Sci U S A. 2008;105(12):4850-4855.
23. Dangles-Marie V, Pocard M, Richon S, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 2007;67(1):398-407.
24. Pardo R, Colin E, Regulier E, et al. Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci. 2006;26(5):1635-1645.
25. Pardo R, Molina-Calavita M, Poizat G, Keryer G, Humbert S, Saudou F. pARIShtt: an optimised expression platform to study huntingtin reveals functional domains required for vesicular trafficking. Mol Brain. 2010;3:17.
26. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12(3):954-961.
27. Lo Sardo V, Zuccato C, Gaudenzi G, et al. An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin. Nat Neurosci. 2012;15(5):713-721.
28. McCaffrey LM, Macara IG. The Par3/aPKC interaction is essential for end bud remodeling and progenitor differentiation during mammary gland morphogenesis. Genes Dev. 2009;23(12):1450-1460.
29. Xue B, Krishnamurthy K, Allred DC, Muthuswamy SK. Loss of Par3 promotes breast cancer metastasis by compromising cell-cell cohesion. Nat Cell Biol. 2013;15(2):189-200.
30. Chen J, Xiao L, Rao JN, et al. JunD represses transcription and translation of the tight junction protein zona occludens-1 modulating intestinal epithelial barrier function. Mol Biol Cell. 2008;19(9):3701-3712.
31. Steffan JS, Kazantsev A, Spasic-Boskovic O, et al. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A. 2000;97(12):6763-6768.
32. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
33. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401-404.
34. Feng Z, Jin S, Zupnick A, et al. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene. 2006;25(1):1-7.
35. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-629.
36. Tang J, Ahmad A, Sarkar FH. The Role of MicroRNAs in Breast Cancer Migration, Invasion and Metastasis. Int J Mol Sci. 2012;13(10):13414-13437.
37. Volinia S, Galasso M, Sana ME, et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A. 2012;109(8):3024-3029.
38. Cascione L, Gasparini P, Lovat F, et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One. 2013;8(2):e55910.
39. Siamakpour-Reihani S, Caster J, Bandhu Nepal D, et al. The role of calcineurin/ NFAT in SFRP2 induced angiogenesis-a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. PLoS One. 2011;6(6):e20412.